# Humira

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/humira
Canonical HTML page: https://getyourbrief.com/entity/humira

## Timeline

- **2029-01-01**: Operational Launch — The new facilities are expected to come online and begin API production.
- **2029-01-01**: Operational Launch — The North Chicago facilities are expected to begin full-scale API production.
- **2029-01-01**: Operational Launch — New facilities expected to come online to support next-gen drug production.
- **2026-03-21**: Construction Start — Anticipated groundbreaking for the two new manufacturing plants.
- **2026-03-20**: Construction Start — Groundbreaking expected for the two new advanced manufacturing sites.
- **2026-03-20**: Construction Start — Anticipated ground-breaking for the two new advanced manufacturing sites.
- **2026-02-23**: Manufacturing Expansion — AbbVie announces $380 million investment for North Chicago API facilities.
- **2026-02-23**: Manufacturing Expansion — AbbVie announces $380M investment for North Chicago API facilities.
- **2026-02-23**: Manufacturing Expansion — AbbVie announces $380 million investment for North Chicago API facilities.
- **2026-01-12**: $100B Pledge — AbbVie commits to $100 billion in U.S. R&D and capital investments over the next decade.
- **2026-01-12**: $100B Pledge — AbbVie commits to $100 billion in U.S. R&D and manufacturing over the next decade.
- **2026-01-12**: $100B Pledge — AbbVie commits to $100 billion in U.S. R&D and capital investments over the next decade.

## Recent coverage (5 stories, network-wide)

### How Rinvoq and Skyrizi Will Drive 21.5% EPS Growth at Q2 Print
2026-07-28 01:06:23 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

AbbVie's second-quarter results, expected to show $3.61 EPS, hinge on the continued clinical and commercial success of Rinvoq and Skyrizi. The Apogee deal underscores a deepening immunology pipeline as Humira fades into the rearview.
Full story: https://getbiobrief.com/story/abbvie-q2-2026-rinvoq-skyrizi-growth

### RBC Capital Initiates AbbVie Coverage with Outperform Rating
2026-02-27 14:46:31 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

RBC Capital has launched coverage of pharmaceutical giant AbbVie with an Outperform rating, signaling confidence in the company's growth trajectory. The initiation suggests that market concerns regarding biosimilar competition for Humira are overstated as newer immunology assets gain significant market share.
Full story: https://getbiobrief.com/story/rbc-capital-abbvie-outperform-rating-analysis

### AbbVie Commits $380M to U.S. Manufacturing in $100B Reshoring Push
2026-02-25 00:14:40 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 3

AbbVie has announced a $380 million investment to expand its manufacturing capabilities in North Chicago, Illinois, marking the first major step in a decade-long $100 billion commitment to U.S. research and development. The move aligns with federal efforts to localize pharmaceutical supply chains and reduce drug prices through direct-to-patient initiatives like TrumpRx.
Full story: https://getbiobrief.com/story/abbvie-380-million-us-manufacturing-investment

### AbbVie Commits $380M to U.S. Manufacturing Amid $100B Domestic Pivot
2026-02-25 00:14:05 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 3

AbbVie has announced a $380 million investment to expand its North Chicago manufacturing campus, marking the first major step in a $100 billion decade-long commitment to U.S. R&D. The initiative aims to localize active pharmaceutical ingredient production while integrating with the Trump administration's 'TrumpRx' program to lower drug costs.
Full story: https://gethealthbrief.com/story/abbvie-380m-us-manufacturing-investment

### AbbVie Commits $380M to U.S. API Production in $100B Supply Chain Pivot
2026-02-25 00:13:32 · Sector: supply · Sentiment: Positive · Impact: 7/10 · Sources: 3

AbbVie has announced a $380 million investment to expand active pharmaceutical ingredient (API) manufacturing in North Chicago, marking the first major step in a $100 billion decade-long commitment to U.S. R&D and production. The move aligns with federal efforts to reshore critical drug supply chains and lower costs through direct-to-patient channels like TrumpRx.
Full story: https://getsupplybrief.com/story/abbvie-380m-us-manufacturing-investment

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.